Bangladesh DGHS 2017: chikungunya
Bangladesh national DGHS Bangladesh Current
National Guideline for Clinical Management of Chikungunya
Disease Control Division, DGHS, and IEDCR, Bangladesh. 2017
Summary checked against the source: 2026-11
National clinical management guideline issued with IEDCR during the 2017 outbreak. Page numbers are the guideline's own.
At a glance
- Suspect chikungunya: sudden fever, severe joint pain and rash ("langra jor"). [p. 8, 11]
- Aedes aegypti (main vector in Bangladesh) and Ae. albopictus, day biters; incubation 3–7 days (2–12). [p. 9–10]
- Confirm: RT-PCR within 5 days of onset, or IgM from day 5 to 28. Rapid ICT kits are unreliable. [p. 11, 22]
- Manage as dengue until dengue is excluded. [p. 18]
- Paracetamol, fluids, rest and cold compresses. No aspirin or NSAIDs for the first 10 days, and only once dengue is excluded. No steroids in the acute stage. [p. 18–20]
- Refractory arthralgia: hydroxychloroquine 200 mg daily (or chloroquine 300 mg) for 4 weeks. [p. 20]
Case definition
| Category | Criteria |
|---|---|
| Possible | Clinical criteria only: fever >38.5 °C and severe arthralgia or arthritis not explained otherwise |
| Probable | Clinical + epidemiological: lives in or visited an epidemic area, with transmission reported within 15 days before onset |
| Confirmed | Laboratory: virus isolation; RT-PCR (within 5 days); IgM in a single serum taken 5–28 days after onset; or a 4-fold rise in IgG 3 weeks apart |
Adapted from BD-DGHS 2017 [p. 11]
Clinical features
- Fever: abrupt, 39–40 °C with chills, usually lasting 24–48 hours. [p. 12]
- Joints: symmetrical, worst in the ankles, wrists and small joints of the hands; also knees, shoulders and spine. Worse in the morning, eased by mild exercise. Pain may ease for 2–3 days and return (saddle-back pattern). The stooped posture gave the disease its name ("that which bends up"). [p. 8, 12]
- Skin: transient maculopapular rash (gone within 48 h); vesiculobullous lesions in children; persistent photosensitive hyperpigmentation; mouth ulcers. [p. 13–14]
- Rare: meningoencephalitis, Guillain–Barré, myelitis; uveitis, retinitis and optic neuritis; myocarditis, hepatitis. [p. 14–16]
- Course: acute symptoms settle in 7–10 days; joint pain can relapse or persist for months to years. [p. 15–16]
| Severity | Features |
|---|---|
| Mild | Low-grade fever, mild arthralgia and myalgia, weakness, rash or itching |
| Moderate | Persistent fever, moderate arthritis, generalised myalgia, hypotension, mild bleeding, retro-orbital pain, oliguria |
| Severe | Persistent high fever, severe arthritis, persistent vomiting or diarrhoea, altered consciousness, bleeding (often from analgesics), shock |
High risk: hypertension, diabetes, cardiovascular disease, older age, pregnancy, COPD, or co-infection (dengue, TB, typhoid, pneumonia, HIV, malaria). Adapted from BD-DGHS 2017 [p. 14–15]
Chikungunya or dengue?
| Chikungunya | Dengue | |
|---|---|---|
| Fever >38.5 °C | +++ | ++ |
| Arthralgia | +++ | +/− |
| Arthritis | + | − |
| Rash | ++ | + |
| Myalgia | + | ++ |
| Haemorrhage | +/− | ++ |
| Shock | − | + |
| Lymphopenia | +++ | ++ |
| Thrombocytopenia | + | +++ |
| Haemoconcentration | − | ++ |
Adapted from BD-DGHS 2017 comparison table [p. 17]
Other differentials: reactive arthritis (enthesitis, after GI or GU infection), serum sickness, rickettsial disease, rheumatic fever (migratory large-joint arthritis, Jones criteria), malaria, leptospirosis (calf pain, conjunctival suffusion, water exposure). [p. 16–17]
Management
Home management: mild and moderate [p. 18–19]
- About 2 litres of salted home fluids a day.
- Paracetamol up to 1 g four times daily (children 50–60 mg/kg/day), if no liver or kidney disease.
- Rest; cold compresses for the joints (avoid heat in the acute stage); avoid exertion; gentle exercise and physiotherapy in recovery.
- No self-medication with aspirin or NSAIDs. Antihistamines for itching.
Admit if: haemodynamic instability (syncope, SBP <90 or pulse pressure <30 mm Hg), urine <500 mL/24 h, altered sensorium, bleeding, disabling joint pain after 3 days of treatment, age >60, infants <1 year, pregnancy, or a high-risk condition. [p. 19]
| In hospital | |
|---|---|
| Fluids | Rehydrate (5% DNS, normal saline; "baby saline" for children) |
| Analgesia | Paracetamol. NSAIDs only after the first 10 days and once dengue is excluded |
| Steroids | No role in the acute stage |
| Bleeding | Platelets if bleeding with platelets <50,000; FFP; vitamin K if INR >2 |
| Neuropathic pain | Amitriptyline, carbamazepine, gabapentin or pregabalin |
| Refractory arthralgia | Hydroxychloroquine 200 mg daily or chloroquine phosphate 300 mg daily for 4 weeks |
| Skin | Zinc oxide cream or calamine for hyperpigmentation and papules |
| Eyes | Ophthalmology referral |
Adapted from BD-DGHS 2017 [p. 19–20]
Special situations
- Pregnancy: rare miscarriage. Infection from 4 days before to 1 day after delivery can pass to the newborn; caesarean section doesn't prevent it. Neonatal disease: fever, poor feeding, oedema, rash, seizures, encephalitis. [p. 21]
- Breastfeeding is encouraged: the virus isn't transmitted in breast milk. [p. 21]
- Lab findings: leucopenia, raised ESR, CRP and SGPT; thrombocytopenia is rare. [p. 21–22]
- No need to isolate the patient; reduce mosquito breeding and day-time bites. [p. 22–23]
Clinical pearls
- Alphavirus (Togaviridae), Aedes vector, like dengue (a flavivirus).
- Severe symmetrical small-joint polyarthralgia with fever and rash; arthritis can persist for months.
- Lymphopenia more than thrombocytopenia.
- Treat as dengue until dengue is excluded: no NSAIDs early.
Classes and levels of evidence
DGHS 2017 is a national programme guideline. It gives standard regimens and operational instructions without grading them by class or level of evidence, so citations on this page give only the page number in the original document. Where it follows WHO guidance, the strength of the WHO recommendation isn't restated.